
ArriVent BioPharma, Inc. Common Stock – NASDAQ:AVBP
ArriVent BioPharma, Inc. Common Stock stock price today
ArriVent BioPharma, Inc. Common Stock stock price monthly change
ArriVent BioPharma, Inc. Common Stock stock price quarterly change
ArriVent BioPharma, Inc. Common Stock key metrics
Market Cap | 860.28M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArriVent BioPharma, Inc. Common Stock stock price history
ArriVent BioPharma, Inc. Common Stock stock forecast
ArriVent BioPharma, Inc. Common Stock financial statements
2023 | 0 | -69.33M |
---|
2024-05-08 | -0.84 | -0.7 |
---|
2023 | 163098000 | 11.80M | 7.24% |
---|
2022 | -43.63M | 0 | 169.72M |
---|---|---|---|
2023 | -55.84M | 0 | 42.85M |
ArriVent BioPharma, Inc. Common Stock alternative data
Feb 2024 | 42 |
---|---|
Mar 2024 | 42 |
Apr 2024 | 40 |
May 2024 | 40 |
Jun 2024 | 40 |
Jul 2024 | 40 |
Dec 2024 | 40 |
ArriVent BioPharma, Inc. Common Stock other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 222222 | 0 |
-
What's the price of ArriVent BioPharma, Inc. Common Stock stock today?
One share of ArriVent BioPharma, Inc. Common Stock stock can currently be purchased for approximately $18.6.
-
When is ArriVent BioPharma, Inc. Common Stock's next earnings date?
Unfortunately, ArriVent BioPharma, Inc. Common Stock's (AVBP) next earnings date is currently unknown.
-
Does ArriVent BioPharma, Inc. Common Stock pay dividends?
No, ArriVent BioPharma, Inc. Common Stock does not pay dividends.
-
How much money does ArriVent BioPharma, Inc. Common Stock make?
ArriVent BioPharma, Inc. Common Stock has a market capitalization of 860.28M. ArriVent BioPharma, Inc. Common Stock made a loss 69.33M US dollars in net income (profit) last year or -$0.7 on an earnings per share basis.
-
What is ArriVent BioPharma, Inc. Common Stock's stock symbol?
ArriVent BioPharma, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "AVBP".
-
What is ArriVent BioPharma, Inc. Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ArriVent BioPharma, Inc. Common Stock?
Shares of ArriVent BioPharma, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does ArriVent BioPharma, Inc. Common Stock have?
As Dec 2024, ArriVent BioPharma, Inc. Common Stock employs 40 workers.
-
When ArriVent BioPharma, Inc. Common Stock went public?
ArriVent BioPharma, Inc. Common Stock is publicly traded company for just a year since IPO on 26 Jan 2024.
-
What is ArriVent BioPharma, Inc. Common Stock's official website?
The official website for ArriVent BioPharma, Inc. Common Stock is arrivent.com.
-
How can i contact ArriVent BioPharma, Inc. Common Stock?
ArriVent BioPharma, Inc. Common Stock can be reached via phone at +62 82774836.
ArriVent BioPharma, Inc. Common Stock company profile:

ArriVent BioPharma, Inc. Common Stock
arrivent.comNASDAQ
40
Biotechnology
Healthcare
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Newtown Square, 19073
:
ISIN: US04272N1028
: